Neurofit IPO Price Set at 14,000 Won.. Demand Forecast Competition Ratio 1087 to 1

[Financial News] Neurofit, a company specializing in AI for brain disease diagnosis and treatment, announced on the 14th through a disclosure that it has set the IPO price at the upper limit of the desired range, 14,000 Won. Neurofit conducted a demand forecast for domestic and international institutional investors from July 4 to 10, resulting in a total of 2,444 institutions participating and recording a competition ratio of 1087.6 to 1.
Interest was high not only from major domestic institutional investors but also from overseas institutional investors, and accordingly, it was tallied that 100% of the institutions participating in the demand forecast (including those not presenting a price) offered a price above the upper limit.
A representative from the listing underwriter Mirae Asset Securities stated, "The success of the demand forecast is analyzed to be driven by the long-term growth potential of Neurofit's brain disease medical AI business, the potential for future revenue growth due to technological superiority, and the anticipation of business promotion with global big pharma."
Bin Jun-gil, co-CEO of Neurofit, said, "We sincerely thank the investors who highly evaluated Neurofit's AI medical solutions covering the entire cycle from diagnosis to treatment of brain diseases, based on our unique technological capabilities."
He continued, "With the Alzheimer's disease treatment being officially prescribed in Korea since the end of last year, the demand for brain imaging analysis is rapidly increasing, and we expect the adoption of our solutions in medical fields to grow along with market expansion. Additionally, as brain imaging analysis technology is essential for the development of brain disease treatments, we will accelerate joint research with global big pharma to continue sustainable growth," he added.
As the IPO price is set at the upper limit of the desired range, Neurofit will conduct a public subscription for two days on the 15th and 16th. The scheduled listing date is July 25.

vrdw88@fnnews.com Kang Jung-mo Reporter